GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Adagio Medical Holdings ADGM · USD

N/A · US listing · 🇺🇸 United States

Compare

1.92

+2858.40%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$602,000

FY2020FY2024

Net income

−$75.0m

FY2020FY2024

Free cash flow

−$31.1m

FY2020FY2024

Shareholders' equity

$19.9m

FY2020FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020
Revenue$602,000$300,000———
Research and development$12.2m$15.4m———
Operating income−$35.0m−$27.9m−$1.0m−$6.6m−$10,000
Net income−$75.0m−$36.6m$1.1m−$6.6m−$10,000
Diluted earnings per share-4.94-2.730.06-0.40—

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020
Total assets$48.4m$6.8m$151.8m$150.4m—
Cash and short-term investments$20.6m$1.4m$100,000$500,000—
Total liabilities$28.5m$47.4m$8.9m$11.2m$100,000
Debt$16.1m$38.3m$100,000——
Shareholders' equity$19.9m−$40.6m$142.9m$139.2m—
Shares outstanding15m13m19m17m17m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020
Cash from operations−$29.5m−$25.7m−$490,000−$1.1m—
Capital spending−$1.6m−$340,000———
Free cash flow−$31.1m−$26.0m−$490,000−$1.1m—

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue———$137,000$185,000$254,000——
Operating income−$5.7m−$4.7m−$7.4m−$8.9m−$11.0m−$6.7m−$8.8m−$2.7m
Net income−$10.1m−$3.9m−$7.7m−$57.4m−$4.6m−$5.0m−$8.0m−$2.2m
Diluted earnings per share-0.66-0.26-0.50-3.34-0.32-0.38-0.60-0.14
Cash from operations−$3.0m−$4.0m−$7.0m−$7.0m−$8.0m−$7.0m−$6.0m—
Total assets$31.5m$35.9m$41.3m$48.4m$107.0m$8.1m$9.3m$40.7m
Cash and short-term investments$4.7m$8.2m$13.0m$20.6m$28.3m$2.0m$87,500$20,200
Debt$21.2m$16.9m$17.7m$16.1m$14.0m——$2.2m
Shareholders' equity−$1.3m$8.7m$12.4m$19.9m$77.0m−$54.0m−$50.0m$25.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income74.2%——
Net income125.3%——

Valuation history

At each fiscal year end

FY2024
Price to earnings-0.1
Price to sales7.1

Share price return

Finished calendar years

20252024
Return2%-81%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.